Cerecor Announces Pricing of Initial Public Offering

BALTIMORE--()--Cerecor Inc. (NASDAQ: CERCU), a clinical-stage biopharmaceutical company with the goal of becoming a leader in the development of innovative drugs that make a difference in the lives of patients with neurological and psychiatric disorders, today announced the pricing of its initial public offering of 4,000,000 units at a public offering price of $6.50 per unit, before underwriting discounts and commissions. Each unit consists of one share of common stock, one Class A warrant to purchase one additional share of common stock and one Class B warrant to purchase one-half additional share of common stock. All of the units are being offered by Cerecor. In addition, Cerecor has granted to the underwriters a 45-day option to purchase up to an additional 600,000 units at the initial public offering price per unit, before underwriting discounts and commission. The units are expected to begin trading on The NASDAQ Capital Market today, October 15, 2015, under the ticker symbol "CERCU."

Maxim Group LLC is acting as sole book running manager for the offering. Laidlaw & Company (UK) Ltd. is acting as lead manager.

The transaction is scheduled to close on October 20, 2015, subject to the terms and conditions of the underwriting agreement. On or prior to December 14, 2015, the units will separate into each of its components and each such component securities will begin trading separately. The common stock is expected to trade on The NASDAQ Capital Market under the symbol "CERC," while the Class A warrants are expected to trade under the ticker symbol "CERCW" and the Class B warrants are expected to trade under the ticker symbol "CERCZ." Cerecor will issue a press release announcing the date such separate trading will begin.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on October 14, 2015. When available, copies of the prospectus related to this offering may be obtained from Maxim Group LLC by mail at 405 Lexington Ave., New York, NY 10174, by calling toll-free: (800) 724-0761, or by email [email protected], or from Laidlaw & Company (UK) Ltd. by mail at 546 Fifth Avenue, 5th Floor, New York, NY, 10036, by calling 212-953-4900, or by email [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

About Cerecor
Cerecor Inc. is a Baltimore-based biopharmaceutical company with the goal of becoming a leader in the development of innovative drugs that make a difference in the lives of patients with neurological and psychiatric diseases by addressing the unmet medical needs of underserved patient segments. We are committed to the development of drugs that improve lives by applying our extensive knowledge and experience in central nervous system disorders. www.cerecor.com

 

 

Contacts

MacDougall Biomedical Communications
Caitlyn Murphy, 781-235-3060
[email protected]

 

Suggested Articles

Novartis is ending early discovery at its R&D site in Shanghai to “rebalance” its discovery and early development efforts.

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year.